Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

In-vitro interaction of azithromycin and fluoroquinolones against gram-positive and gram-negative bacteria Matthew W. Ruble, Deborah H. Gilbert, Stephen.

Grepafloxacin: microbiological properties

Approach to diagnosis of infective endocarditis

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Herpes zoster in non-hospitalized children

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

In vitro effects of cefotaxime and ceftriaxone on Salmonella typhi within human monocyte-derived macrophages B. Ekinci, A.Y. Coban, A. Birinci, B. Durupinar,

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98 J. Robert, E. Cambau, K. Grenet, D.

A. Domínguez-Gil Hurlé, A. Sánchez Navarro, M.J. García Sánchez

A.E. Muller, U. Theuretzbacher, J.W. Mouton

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli R.A. Hickman, D. Hughes,

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca N. Moustaoui,

Vector control: a cornerstone in the malaria elimination campaign

Inga Odenholt, Elisabeth Löwdin, Otto Cars

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Cephalosporins: a pharmacological update

Laboratory diagnosis and biosafety issues of biological warfare agents

CMI editorial report 2011 Clinical Microbiology and Infection

Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections P.S. Hicks, B.

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria Inga Odenholt, Elisabeth Löwdin,

Haemophilus influenzae serotype b conjugate vaccine failure in twelve countries with established national childhood immunization programmes S. Ladhani,

Sepsis and neutropenia induced by clozapine

Elements of design: the knowledge on which we build

Evidence for a true post-β-lactamase-inhibitor effect of clavulanic acid against Klebsiella pneumoniae and Haemophilus influenzae V. Murbach, N. Dhoyen,

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

B. Sádaba, J.R. Azanza, M.A. Campanero, E. García-Quetglas

Laboratory diagnosis of Clostridium difficile disease

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

A. Bryskier Clinical Microbiology and Infection

Brucella detection in blood: comparison of the BacT/Alert standard aerobic bottle, BacT/Alert FAN aerobic bottle and BacT/Alert enhanced FAN aerobic bottle.

Pathogenesis of catheter-related infections: lessons for new designs

J. Garau Clinical Microbiology and Infection

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens.

Training in infectious diseases and tropical medicine in Britain

Reducing antibiotic use in influenza: challenges and rewards

A.P. Underwood, J. Green Clinical Microbiology and Infection

Fibronectin concentrations in catheter sepsis

Clinical infection services—the Leiden experience

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

The influence of protein binding on the antibacterial activity of faropenem against Haemophilus influenzae I. Gustafsson, O. Cars Clinical Microbiology.

W. Eugene Sanders, Christine C. Sanders

Overview of cefixime use in community-acquired infections

The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model Alasdair P. MacGowan,

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release J. SjöUlin,

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

In vitro activity of evernimicin and selected antibiotics against methicillin-resistant staphylococci: a 24-country study R. Goering, C.-E. Nord, R.

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore,

Typing of Clostridium difficile

New patterns of HIV-1 resistance during HAART

Localized Mycobacterium avium complex infection in a patient on HAART

The future of diagnostic bacteriology

Presentation transcript:

Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation E. Löwdin, O. Cars, I. Odenholt Clinical Microbiology and Infection Volume 8, Issue 10, Pages 646-653 (October 2002) DOI: 10.1046/j.1469-0691.2002.00441.x Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 The concentration of amoxicillin in the in vitro kinetic model corresponding to a dose of 875 mg b.i.d. (♦), 500 mg t.i.d. (▪) and of the pharmacokinetically enhanced formulation 2000 mg b.i.d. (▴). Clinical Microbiology and Infection 2002 8, 646-653DOI: (10.1046/j.1469-0691.2002.00441.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 The rate and extent of killing of amoxicillin/clavulanic acid at a concentration corresponding to a dose of 875/125 mg b.i.d. (▪) and 500/125 mg t.i.d. (♦) against H. influenzae LH 2803 in the in vitro kinetic model (mean ± SD). Clinical Microbiology and Infection 2002 8, 646-653DOI: (10.1046/j.1469-0691.2002.00441.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 3 (a) The rate and extent of killing of amoxicillin/clavulanic acid at a concentration corresponding to a dose of 875/125 mg b.i.d. against the clinical strains of H. influenzae in the in vitro kinetic model (mean ± SD). (b) The rate and extent of killing of amoxicillin/clavulanic acid at a concentration corresponding to a dose of 500/125 mg t.i.d. against the clinical strains of H. influenzae in the in vitro kinetic model. Clinical Microbiology and Infection 2002 8, 646-653DOI: (10.1046/j.1469-0691.2002.00441.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 4 The rate and extent of killing of amoxicillin/clavulanic acid simulating the slow-release compound against H. influenzae LH 2803 and the clinical strains of H. influenzae in the in vitro kinetic model (mean ± SD). Clinical Microbiology and Infection 2002 8, 646-653DOI: (10.1046/j.1469-0691.2002.00441.x) Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions